Drug Safety

, Volume 39, Issue 6, pp 543–559 | Cite as

Long-Term Outcomes of Short-Term Statin Use in Healthy Adults: A Retrospective Cohort Study

  • Ishak A. Mansi
  • Jenny English
  • Song Zhang
  • Eric M. Mortensen
  • Ethan A. Halm
Original Research Article

Abstract

Introduction

Data suggest that the beneficial cardiovascular effects of statins are maximized after the first year of statin use; yet, the timeline of statin-associated adverse events is not well delineated.

Objective

To examine the associations of short-term statin use (≤1 year) with short- and long-term adverse events and beneficial cardiovascular outcomes in a ‘healthy’ cohort.

Participants and Methods

A cohort study of a healthy Tricare population (fiscal year [FY] 2002 through FY 2011) who have no cardiovascular disease, major comorbidities requiring medications, or functional limitations. Statin users used statins for 90–365 days during FY 2005 as their only prescription medication. Nonusers had medical encounters but did not receive prescription medications during FY 2005, and did not receive any statins throughout the study period from FY 2002 to FY 2011. Outcomes were the occurrence of major acute cardiovascular events, diabetes mellitus and its complications, kidney diseases, musculoskeletal diseases, obesity, cataracts, malignancy, and death.

Results

We matched 1525 statin users to 1525 nonusers. During the follow-up period (FY 2006 to FY 2011), statin users had significantly higher odds of developing diabetes and diabetic complications that persisted throughout follow-up (odds ratio [OR] 1.93, 95 % confidence interval [CI] 1.55–2.41 and OR 2.15, 95 % CI 1.20–3.86, respectively). Short-term statin use was not associated with decreased odds of major acute cardiovascular events (OR 1.17, 95 % CI 0.72–1.92). There were no differences in risks of kidney diseases, musculoskeletal diseases, or malignancy.

Conclusions

Short-term statin use for primary prevention in this healthy cohort was associated with an increased risk of long-term diabetes and diabetic complications without cardiovascular benefits. Further study using pragmatic studies and prospective observational studies appropriately equipped to eliminate unidentified confounders are urgently needed.

Notes

Compliance with Ethical Standards

Funding

Drs. Halm and Mortensen were supported in part by a grant from the Agency for Healthcare Research and Quality (R24 HS022418) for the University of Texas Southwestern Center for Patient-Centered Outcomes Research.

No funding was provided for the conduct of this study. This material is the result of work supported with resources and the use of facilities at the VA North Texas Health Care System and the University of Texas Southwestern.

Conflicts of interest

Ishak Mansi, Jenny English, Song Zhang, Eric Mortensen, and Ethan Halm declare that they have no conflicts of interest that are directly relevant to the content of this study.

Disclaimer

The views expressed herein are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Defense, VA Healthcare administration, or the US Government. The authors are employees of the US Government. This work was prepared as part of their official duties and, as such, there is no copyright to be transferred.

Supplementary material

40264_2016_412_MOESM1_ESM.pdf (143 kb)
Supplementary material 1 (PDF 142 kb)

References

  1. 1.
    Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults. J Gen Intern Med. 2015;30(11):1599–610.CrossRefPubMedGoogle Scholar
  3. 3.
    Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med. 2014;174(7):1038–45.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lee DS, Markwardt S, Goeres L, Lee CG, Eckstrom E, Williams C, et al. Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med. 2014;174(8):1263–70.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4):266–75.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ridker PM, Cook NR. Comparing cardiovascular risk prediction scores. Ann Intern Med. 2015;162(4):313–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J. 2002;23(3):207–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMedGoogle Scholar
  10. 10.
    Mansi I. Statin adverse events in primary prevention: between randomized trials and observational studies. Am J Med Sci. 2015;350(4):330–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Moniz C. Outpatient workload (RVU) predictors: age, gender and beneficiary category. Graduate Management Project. Baltimore, MD: US Army Medical Department Center and School, Medicine JH; 2008 June 15, Report No.: Contract No.: 34-08.Google Scholar
  12. 12.
    Gantt CJ, Neely JA, Villafana IA, Chun CS, Gharabaghli SM. Analysis of weight and associated health consequences of the active duty staff at a major Naval medical center. Mil Med. 2008;173(5):434–40.CrossRefPubMedGoogle Scholar
  13. 13.
    George SZ, Childs JD, Teyhen DS, Wu SS, Wright AC, Dugan JL, et al. Brief psychosocial education, not core stabilization, reduced incidence of low back pain: results from the Prevention of Low Back Pain in the Military (POLM) cluster randomized trial. BMC Med. 2011;9(1):128.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lilly SM, Mortensen EM, Frei CR, Pugh MJ, Mansi IA. Comparison of the risk of psychological and cognitive disorders between persistent and nonpersistent statin users. Am J Cardiol. 2014;114(7):1035–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ Can Med Assoc J J de l’Association Med Can. 2015;187(3):174–80.CrossRefGoogle Scholar
  17. 17.
    Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS) for ICD-9-CM. Databases and related tools from the healthcare cost and utilization project (HCUP) [Internet]. 2012 01/01/2012: [Appendix A p.]. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Accessed 16 Mar 2015.
  18. 18.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27(Suppl 2):B10–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011;13(1):R32.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI, Alibhai A, et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res. 2008;43(4):1424–41.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Goff SL, Pekow PS, Markenson G, Knee A, Chasan-Taber L, Lindenauer PK. Validity of using ICD-9-CM codes to identify selected categories of obstetric complications, procedures and co-morbidities. Paediatr Perinat Epidemiol. 2012;26(5):421–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Mansi I, Mortensen E. The controversy of a wider statin utilization: why? Expert Opin Drug saf. 2013;12(3):327–37.CrossRefPubMedGoogle Scholar
  24. 24.
    Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15):2051–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ho D, Imai K, King G, Stuart E. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15:199–236.CrossRefGoogle Scholar
  26. 26.
    Ho D, Imai K, King G, Stuart E. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28.CrossRefGoogle Scholar
  27. 27.
    Hansen BB. Full matching in an observational study of coaching for the SAT. J Am Stat Assoc. 2004;99(467):609–18.CrossRefGoogle Scholar
  28. 28.
    Hansen BB, Bowers J. Covariate balance in simple, stratified and clustered comparative studies. Stat Sci. 2008;23(2):219–36.CrossRefGoogle Scholar
  29. 29.
    Thoemmes F. An SPSS R menu for propensity score matching. 2011. http://www.arxiv.org. Accessed 21 May 2015.
  30. 30.
    Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates Publishers; 1988.Google Scholar
  31. 31.
    Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS, SAS Global Forum 2012—Statistics and Data Analysis; Paper 335-2012. http://support.sas.com/resources/papers/proceedings12/335-2012.pdf.
  32. 32.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.CrossRefPubMedGoogle Scholar
  33. 33.
    Army Regulation 40-501; Standards of Medical Fitness. Washington, DC: Headquarters, Medical Services, Department of the Army, 14 December 2007. 2007.Google Scholar
  34. 34.
    Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 1987;106(6):793–800.CrossRefPubMedGoogle Scholar
  35. 35.
    Weiner DA, Ryan TJ, McCabe CH, Chaitman BR, Sheffield LT, Ferguson JC, et al. Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease. J Am Coll Cardiol. 1984;3(3):772–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.PubMedGoogle Scholar
  37. 37.
    Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364(9436):771–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477–86.CrossRefPubMedGoogle Scholar
  39. 39.
    Tonkin A, Aylward P, Colquhoun D, Glasziou P, Harris P, MacMahon S, Magnus P, Newel D, Nestel P, Sharpe N, Hunt D. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–57.CrossRefGoogle Scholar
  40. 40.
    Enas EA, Kuruvila A, Khanna P, Pitchumoni CS, Mohan V. Benefits and risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians—a population with the highest risk of premature coronary artery disease and diabetes. Indian J Med Res. 2013;138(4):461–91.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Porta M, Curletto G, Cipullo D, Rigault de la Longrais R, Trento M, Passera P, et al. Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care. 2014;37(6):1668–74.CrossRefPubMedGoogle Scholar
  42. 42.
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.CrossRefPubMedGoogle Scholar
  43. 43.
    Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172(2):144–52.CrossRefPubMedGoogle Scholar
  44. 44.
    Park ZH, Juska A, Dyakov D, Patel RV. Statin-associated incident diabetes: a literature review. Consult Pharm. 2014;29(5):317–34.CrossRefPubMedGoogle Scholar
  45. 45.
    Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999;126(5):1205–13.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342–7.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881–92.CrossRefPubMedGoogle Scholar
  48. 48.
    Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metab Clin Exp. 2014;63(6):735–45.CrossRefPubMedGoogle Scholar
  49. 49.
    Sattar N, Taskinen MR. Statins are diabetogenic–myth or reality? Atheroscler Suppl. 2012;13(1):1–10.CrossRefPubMedGoogle Scholar
  50. 50.
    Henriksbo BD, Schertzer JD. Is immunity a mechanism contributing to statin-induced diabetes? Adipocyte. 2015;4(4):232–8.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351–61.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Frayling TM. Statins and type 2 diabetes: genetic studies on target. Lancet. 2015;385(9965):310–2.CrossRefPubMedGoogle Scholar
  53. 53.
    Liew SM, Lee PY, Hanafi NS, Ng CJ, Wong SS, Chia YC, et al. Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes. Diabetol Metab Syndr. 2014;6:53.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med Off Publ Am Fed Clin Res. 2009;57(3):495–9.Google Scholar
  55. 55.
    Aguirre L, Hijona E, Macarulla MT, Gracia A, Larrechi I, Bujanda L, et al. Several statins increase body and liver fat accumulation in a model of metabolic syndrome. J Physiol Pharmacol Off J Pol Physiol Soc. 2013;64(3):281–8.Google Scholar
  56. 56.
    Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172(15):1180–2.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Danaei G, Rodriguez LA, Cantero OF, Logan R, Hernan MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22(1):70–96.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355(8):779–87.CrossRefPubMedGoogle Scholar
  59. 59.
    Allison DB, Faith MS, Heo M, Townsend-Butterworth D, Williamson DF. Meta-analysis of the effect of excluding early deaths on the estimated relationship between body mass index and mortality. Obes Res. 1999;7(4):342–54.CrossRefPubMedGoogle Scholar
  60. 60.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.CrossRefPubMedGoogle Scholar
  61. 61.
    Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women’s Health Study. JAMA Intern Med. 2014;174(12):1964–71.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Memtsoudis SG, Bombardieri AM, Ma Y, Walz JM, Chiu YL, Mazumdar M. Mortality of patients with respiratory insufficiency and adult respiratory distress syndrome after surgery: the obesity paradox. J Intensive Care Med. 2012;27(5):306–11.CrossRefPubMedGoogle Scholar
  63. 63.
    Scott SK, Rabito FA, Price PD, Butler NN, Schwartzbaum JA, Jackson BM, et al. Comorbidity among the morbidly obese: a comparative study of 2002 US hospital patient discharges. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2006;2(2):105–11.CrossRefGoogle Scholar
  64. 64.
    Vila-Corcoles A, Ochoa-Gondar O, Llor C, Hospital I, Rodriguez T, Gomez A. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur Respir J. 2005;26(6):1086–91.CrossRefPubMedGoogle Scholar
  65. 65.
    Allareddy V, Rampa S, Anamali S, Lee MK, Allareddy V, Nalliah RP. Obesity and its association with comorbidities and hospital charges among patients hospitalized for dental conditions. Journal of investigative and clinical dentistry. 2015. doi: 10.1111/jicd.12146] (Epub ahead of print).
  66. 66.
    Wier L, Encinosa W. Obesity in children: Hospitalizations from 2000 to 2009. HCUP Statistical Brief #138. July 2012. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb138.pdf. Accessed 16 Mar 2015.
  67. 67.
    Weiss A, Elixhauser A. Obesity-related hospitalizations, 2004 versus 2009. HCUP Statistical Brief #137. July 2012. Agency for Healthcare Research and Quality. Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb137.pdf. Accessed 16 Mar 2015.
  68. 68.
    Elixhauser A, Steiner C. Obese patients in US Hospitals, 2004. HCUP Statistical Brief #20. December 2006. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb20.pdf. Accessed 16 Mar 2015.
  69. 69.
    Kiss Z, Nagy L, Reiber I, Paragh G, Molnar MP, Rokszin G, et al. Persistence with statin therapy in Hungary. Arch Med Sci. 2013;9(3):409–17.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland (outside the USA) 2016

Authors and Affiliations

  • Ishak A. Mansi
    • 1
    • 2
    • 3
  • Jenny English
    • 4
  • Song Zhang
    • 3
  • Eric M. Mortensen
    • 1
    • 2
    • 3
  • Ethan A. Halm
    • 2
    • 3
  1. 1.Medicine ServicesVA North Texas Health Care SystemDallasUSA
  2. 2.Department of Internal MedicineUniversity of Texas Southwestern Medical CenterDallasUSA
  3. 3.Department of Clinical SciencesUniversity of Texas Southwestern Medical CenterDallasUSA
  4. 4.Department of the ArmyPatient Administration Systems and Biostatistics Activity (PASBA)Fort Sam HoustonUSA

Personalised recommendations